Harness the Power of HTG's Propietary Transcriptome Panel

Building on more than a decade of pioneering innovation and partnerships with biopharma leaders and major academic institutes, HTG's RNA platform technologies make the development of life science tools and diagnostics more effective and cost-efficient, enabling researchers to interrogate the entire transcriptome with smaller sample requirements and higher success rates.

The University of Texas MD Anderson Cancer Center

The University of Texas MD Anderson Cancer Center

Saint John’s Cancer Institute

Saint John’s Cancer Institute

Duke University Medical Center

Duke University Medical Center

Fundación Instituto Valenciano de Oncologia

Fundación Instituto Valenciano de Oncologia

Tyrolpath Obrist Brunhuber GmbH

Tyrolpath Obrist Brunhuber GmbH


        University Hospital Essen

University Hospital Essen

Johannes Wesling Hospital Minden

Johannes Wesling Hospital Minden

Alacris Theranostics GmbH

Alacris Theranostics GmbH

Centre Leon Berard

Centre Leon Berard

The Larner College of Medicine at the University of Vermont

The Larner College of Medicine at the University of Vermont

Mayo Clinic

Mayo Clinic

Universitätsklinikum Tübingen

Universitätsklinikum Tübingen

Institute of Immunobiology, Kantonsspital St. Gallen

Institute of Immunobiology, Kantonsspital St. Gallen

University Hospital Basel

University Hospital Basel

Imperial College London

Imperial College London

Featured Publication

Overview of the Design and Performance of the HTG Transcriptome Panel

This White Paper summarizes the data generated using the HTG Transcriptome Panel from Feasibility through Verification, including comparison to RNA-Seq.
 

READ PUBLICATION

HTG Molecular News & Events

HTG and Icahn School of Medicine at Mount Sinai Announce Bladder Cancer Research Collaboration

HTG’s Innovative Transcriptome Panel Technology to be Leveraged in Retrospective Studies TUCSON, Ariz. , Nov. 17, 2021 (GLOBE NEWSWIRE) – HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company advancing precision medicine through its innovative transcriptome-wide profiling…

Keep Reading

HTG Molecular Diagnostics Reports Third Quarter 2021 Results

Call scheduled for today, November 10, at 4:30 pm ET TUCSON, Ariz. , Nov. 10, 2021 (GLOBE NEWSWIRE) – HTG Molecular Diagnostics , Inc. (Nasdaq: HTGM) (HTG), a life science company advancing precision medicine through its innovative transcriptome-wide profiling technology, today reported its…

Keep Reading

HTG Molecular Diagnostics to Announce Third Quarter 2021 Financial Results and Host Conference Call on Wednesday, November 10

TUCSON, Ariz. , Nov. 02, 2021 (GLOBE NEWSWIRE) – HTG Molecular Diagnostics , Inc. (Nasdaq: HTGM), a life science company advancing precision medicine through its transcriptome-wide technology, today announced that it will report its financial results for the third quarter ended September 30, 2021…

Keep Reading

Resources

Find product information, specifications and gene lists here. 

Case Studies

Brochures

Gene Lists

Product Sheets

Tech Notes

Safety Data Sheets

Videos


Support

Log in to your account to view technical manuals, package inserts, and other information related to your HTG EdgeSeq system or panels. 

Log in to your account

Page last updated November 09, 2021

Ready to get started?

HTG is focused on delivering exceptional molecular profiling products and services. Contact us to find out how our unique technology can benefit you.

Get in Touch